CADL Candel Therapeutics, Inc.

Candel Therapeutics Inc is a late clinical stage biopharmaceutical company. It is focused on helping patients fight cancer with oncolytic viral immunotherapies.

As of 12/03/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/23/2021
Outstanding shares:  28,689,842
Average volume:  37,385
Market cap:   $286,324,623
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    137404109
ISIN:        US1374041093
Valuation   (See tab for details)
PE ratio:   -7.15
PB ratio:   4.28
PS ratio:   0.00
Return on equity:   -76.52%
Net income %:   -38,869.35%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy